Machine-guided design to enable gene therapy
At Dyno Therapeutics we are expanding the boundaries of gene therapy by accelerating the transition of genetic medicine from the lab to the clinic for the treatment of millions of patients.
Capsids derived from Adeno-associated virus (AAV) are the vector of choice for gene therapy, yet even the most widely used versions are not optimal for disease treatment. There has not been a systematic way to achieve multi-functional, disease-specific enhancement of AAV capsids - until now.
Dyno’s groundbreaking engineering platform combines machine learning with next-gen DNA synthesis and high-throughput DNA sequencing to program capsids with improved functions like precision delivery and immune system evasion, overcoming the barriers that separate gene therapy research from real-world therapies.
Our goals are common. Our approach is not. Together, we aim to deliver innovative treatments that fulfill the promise of genetic medicine.